VolitionRx Limited (VNRX)
VNRXAMEXBiotechnology: In Vitro & In Vivo Diagnostic Substances
$0.1990
-0.0310 (-13.48%) today
Regular session, Nov 16, 11:08 AM ET
- Market cap
- $7.17m
- P/E
- –
- EPS, last 4 quarters
- $-2.80
- Dividend yield
- –
- Day range
- $0.1900 to $0.2200
- 52-week range
- $0.1564 to $7.73
- Average volume
- –
- Previous close
- $0.2300
Earnings
next estimate $-0.1900Next report
Dec 2025
-25.0%
Mar 2026
-17.1%
Jun 2026
-14.7%
Sep 2026
+42.9%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $447.0k | $985.0k | $399.0k | $1.61m |
| Gross profit | $447.0k | $985.0k | $399.0k | $1.61m |
| Operating income | -$4.82m | -$5.35m | -$4.18m | -$3.33m |
| Net income | -$6.27m | -$6.67m | -$7.33m | -$3.80m |
Last four quarters: revenue $3.44m, margin -698.5%, free cash flow -$20.59m
News
8 latest- VolitionRx (VNRX) Q3 2026 Earnings Call TranscriptThe Motley Fool · 3 days ago
- VolitionRx Limited Announces Third Quarter 2026 Financial Results and Business UpdateFintel · 3 days ago
- VolitionRx Limited CEO Cameron Reynolds Agrees to Further Temporary Salary Reduction to $236,970.50Fintel · 3 days ago
- VolitionRx Limited Announces $500,000 Partial Prepayment of Convertible NoteFintel · Oct 27, 2026
- VolitionRx Consensus Price Target Decreased by 17.44% to $13.89Fintel · Oct 2, 2026
- Volition Validates Nu.Q NETs Biomarker In Sepsis; Stock Down RTTNews · Aug 26, 2026
- Volition (VNRX) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 20, 2026
- VolitionRx (VNRX) Price Target Increased by 1,618.09% to 29.79Fintel · May 14, 2026
The company
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- AMEX
- Region
- Asia
- Website
- volition.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.